Sexton Riley LLP represented Janssen Biotech, Inc., a Johnson & Johnson company, in its December 2020 research collaboration agreement with Xencor, Inc. focused on the discovery of bispecific antibodies against CD28, an immune co-stimulatory receptor on T cells, and an undisclosed prostate tumor target. https://investors.xencor.com/news-releases/news-release-details/xencor-enters-collaboration-janssen-aim-discover-novel-cd28
top of page
bottom of page